BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 2910788)

  • 41. The clinical value of squamous cell carcinoma antigen in cancer of the uterine cervix.
    de Bruijn HW; Duk JM; van der Zee AG; Pras E; Willemse PH; Boonstra H; Hollema H; Mourits MJ; de Vries EG; Aalders JG
    Tumour Biol; 1998; 19(6):505-16. PubMed ID: 9817980
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative studies of CAM 123-6 and carcinoembryonic antigen for the serological detection of pulmonary adenocarcinoma.
    Kohno N; Hirasawa Y; Kondo K; Fujioka S; Fujino S; Abe M; Yokoyama A; Hiwada K; Watanabe K; Nishimura J
    Cancer Detect Prev; 1997; 21(2):124-8. PubMed ID: 9101072
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The importance of the SCC antigen in the diagnosis and follow-up of cervix carcinoma. A cooperative study of the Gynecologic Tumor Marker Group (GTMG)].
    Crombach G; Würz H; Herrmann F; Kreienberg R; Möbus V; Schmidt-Rhode P; Sturm G; Caffier H; Kaesemann H
    Dtsch Med Wochenschr; 1989 May; 114(18):700-5. PubMed ID: 2714197
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [A clinical study on multiple tumor markers following therapy in patients with uterine cervical carcinoma].
    Hiura M; Yorishima M; Tanaka M; Yokoyama T; Myoga H; Chiba T; Nakanishi Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 May; 42(5):471-8. PubMed ID: 2373919
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Validity of Using Human Squamous Cell Carcinoma Associated Antigen and Cytokeratin 19 Fragment Antigen 21-1 to Predict Postoperative Adjuvant Radiotherapy for Nonbulky Early-Stage Squamous Cell Carcinoma of the Cervix.
    Liu CZ; Zeng HX; Zhao JJ; Rong Y; Mo ZL; Li LA; Zhang JQ
    Int J Gynecol Cancer; 2017 Jun; 27(5):994-1000. PubMed ID: 28498239
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tumour markers and their prognostic value in adenocarcinoma of the cervix.
    Ngan HY; Cheung AN; Lauder IJ; Cheng DK; Wong LC; Ma HK
    Tumour Biol; 1998; 19(6):439-44. PubMed ID: 9817971
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix.
    Bolli JA; Doering DL; Bosscher JR; Day TG; Rao CV; Owens K; Kelly B; Goldsmith J
    Gynecol Oncol; 1994 Nov; 55(2):169-73. PubMed ID: 7959279
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Prediction of the recurrence of squamous cell carcinoma of the uterine cervix by monitoring serum TA-4].
    Oishi T; Maruo T; Yamasaki M; Mochizuki M
    Nihon Sanka Fujinka Gakkai Zasshi; 1987 May; 39(5):799-806. PubMed ID: 3598275
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adenocarcinoma of the uterine cervix. Prognostic significance of pretreatment serum CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen levels in relation to clinical and histopathologic tumor characteristics.
    Duk JM; De Bruijn HW; Groenier KH; Fleuren GJ; Aalders JG
    Cancer; 1990 Apr; 65(8):1830-7. PubMed ID: 2317761
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
    Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
    Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Squamous cell carcinoma antigen, circulating immune complexes, and immunoglobulins in monitoring squamous cell carcinoma of head and neck: a study of the hellenic co-operative oncology group (HeCOG).
    Makrantonakis P; Pectasides D; Aggouridakis C; Visvikis A; Daniilidis J; Fountzilas G
    Am J Clin Oncol; 1999 Dec; 22(6):542-9. PubMed ID: 10597736
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Assessment of urinary beta-core fragment of hCG as a tumor marker of cervical cancer].
    Kinugasa M; Nishimura R; Hasegawa K; Okamura M; Kimura A; Ohtsu F; Takeuchi K
    Nihon Sanka Fujinka Gakkai Zasshi; 1992 Feb; 44(2):188-94. PubMed ID: 1545171
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic utility of squamous cell carcinoma antigen in carcinoma of the cervix: association with pre- and posttreatment FDG-PET.
    Olsen JR; Dehdashti F; Siegel BA; Zighelboim I; Grigsby PW; Schwarz JK
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):772-7. PubMed ID: 20888130
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum CYFRA 21-1 assay in squamous cell carcinoma of the cervix.
    Ferdeghini M; Gadducci A; Annicchiarico C; Prontera C; Malagnino G; Castellani C; Facchini V; Bianchi R
    Anticancer Res; 1993; 13(5C):1841-4. PubMed ID: 7505543
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Squamous cell carcinoma antigen and carcinoembryonic antigen levels as prognostic factors for the response of cervical carcinoma to chemotherapy.
    Meier W; Eiermann W; Stieber P; Fateh-Moghadam A; Schneider A; Hepp H
    Gynecol Oncol; 1990 Jul; 38(1):6-11. PubMed ID: 2191907
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Usefulness of the SCC, CEA, CYFRA 21.1, and CRP markers for the diagnosis and monitoring of cervical squamous cell carcinoma].
    Chmura A; Wojcieszek A; Mrochem J; Walaszek-Gruszka A; Deja R; Masłyk B; Bartnik W; Sodowski K
    Ginekol Pol; 2009 May; 80(5):361-6. PubMed ID: 19548456
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Squamous cell carcinoma antigen in patients with cancer of the uterine cervix.
    Fuith LC; Daxenbichler G
    Gynecol Obstet Invest; 1988; 26(1):77-82. PubMed ID: 3169633
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of serum human telomerase reverse transcriptase as a novel marker for cervical cancer.
    Porika M; Tippani R; Mohammad A; Bollam SR; Panuganti SD; Abbagani S
    Int J Biol Markers; 2011; 26(1):22-6. PubMed ID: 21319134
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasma levels and diagnostic utility of macrophage-colony stimulating factor, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 as tumor markers in cervical cancer patients.
    Zajkowska M; Zbucka-Krętowska M; Sidorkiewicz I; Lubowicka E; Gacuta E; Szmitkowski M; Chrostek L; Ławicki S
    Tumour Biol; 2018 Jul; 40(7):1010428318790363. PubMed ID: 30052166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.